SYSNIB
LIVE

Serial Number

79292224

Owner

NITTO BOSEKI CO., LTD.

Attorney

M. Scott Alprin

Filing Date

Jun 18, 2020

Add to watchlist:

No watchlists yet
View on USPTO

SYSNIB Trademark

Serial Number: 79292224 • Registration: 6422359

SYSNIB is a trademark filed by NITTO BOSEKI CO., LTD. on June 18, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

NITTO BOSEKI CO., LTD. (23 trademarks)

GONOME, FUKUSHIMA , JP

Entity Type: 11

Trademark Details

Filing Date

June 18, 2020

Registration Date

July 20, 2021

Published for Opposition

May 4, 2021

Goods & Services

Laboratory apparatus and instruments for treating biological tissue for pathological studies; laboratory apparatus, instruments and their structural parts and fittings for treating biological tissue not for medical purposes; laboratory apparatus and instruments for sample pre-treatment system and sample preparation system; measuring and testing machines and instruments for genetic analysis; measuring or testing machines and instruments, namely, flow cytometers, cell-sorters, imaging cytometers, and imaging analyzers; biological cell testing apparatus for laboratory purposes; biological tissue testing apparatus for laboratory purposes

Pharmaceutical preparations for the treatment of cancer; drugs for medical purposes for the treatment of cancer; medicines for human purposes for the treatment of cancer; in vitro diagnostic preparations for medical purposes; diagnostic preparations for medical purposes; diagnostic test reagents for medical purposes; biochemical preparations for medical purposes for the treatment of cancer; biological reagents for medical purposes; biological preparations for medical purposes for the treatment of cancer; chemical reagents for medical purposes; reagents for medical purposes; clinical diagnostic reagents for medical purposes; diagnostic agents, preparations and substances for medical purposes; chemical preparations for medicinal purposes for the treatment of cancer; antibodies for medical purposes for the treatment of cancer; diagnostic biomarker reagents for medical purposes

Clinical pathological examination and cytological diagnostics for medical purposes; medical testing for diagnostic purposes; medical testing for disease prediction; pathological examination for medical purposes and providing medical information relating thereto; genetic testing for medical purposes; medical and health services relating to DNA, genetics and genetic testing; medical services; medical information

Diagnostic apparatus for medical purposes for testing cancer cells, cancerous nuclei, lymphocytes, nucleoprotein, DNA, and RNA; biological cell testing apparatus for medical and medical diagnostic purposes; biological tissue testing apparatus for medical and medical diagnostic purposes; medical apparatus for clinical diagnosis of cancer; medical apparatus for pathologic diagnosis; medical apparatus and instruments for pathologic examination

Genetic testing for scientific research purposes; development, testing, inspection for quality control purposes, and research of pharmaceuticals and biological preparations; testing of pharmaceuticals, inspection for quality control purposes and medical research in the fields of medical treatment method and technology; medical research; biological research; chemistry services, namely, chemistry consultation, research in the fields of biology, oncology and pathology; chemical and biological laboratory services, namely, biological, oncological and pathological research; laboratory research and analysis services in the fields of biology, oncology and pathology

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Oct 7, 2023 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Feb 5, 2023 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 5, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 17, 2021 FICS
FINAL DISPOSITION PROCESSED
Nov 17, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 20, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 20, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 4, 2021 NPUB
PUBLISHED FOR OPPOSITION
May 4, 2021 PUBO
NOTIFICATION PROCESSED BY IB
May 2, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 14, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 14, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 14, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 1, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 31, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 30, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 30, 2021 TROA
REFUSAL PROCESSED BY IB
Nov 14, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 28, 2020 RFCS
REFUSAL PROCESSED BY MPU
Oct 28, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 5, 2020 RFCR
NON-FINAL ACTION WRITTEN
Oct 4, 2020 CNRT
ASSIGNED TO EXAMINER
Sep 22, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 25, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 21, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 20, 2020 REPR